Shanghai MicroPort MedBot (2252) Stock Overview

Shanghai MicroPort MedBot (Group) Co., Ltd. engages in the research and development, design, manufacture, and sale of surgical robots in the People's Republic of China. It offers Toumai, a laparoscopic surgical robot for use in urologic, gynecologic, thoracic, and general surgeries; DFVision, a 3D electronic laparoscope, which is used in laparoscopic surgeries for abdominal, thoracic, and pelvic organs; SkyWalker, an orthopedic surgical robot for knee arthroplasty and hip arthroplasty; R-One, a vascular interventional surgical robot for coronary angioplasty; and iSR'obot, a Mona Lisa robotic transperineal prostate biopsy system. The company also provides spine surgical robots for spine surgery; trans-bronchial surgical robots for trans-bronchial diagnosis and treatment; TAVR surgical robots for heart valve replacement surgery; and thoracic and abdominal puncture surgical robot for percutaneous lung biopsy and percutaneous liver biopsy. In addition, it manufactures parts of surgical robot devices; engages in assembly and distribution of surgical robot devices; research and development of system, as well as investment activities. Shanghai MicroPort MedBot (Group) Co., Ltd. was founded in 2014 and is based in Shanghai, China. Shanghai MicroPort MedBot (Group) Co., Ltd. operates as a subsidiary of Shanghai Latent Artificial Intelligence Co., Ltd.